Drugs / GSK159802
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00364273 | Aug 2005 → Jul 2006 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK159802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00364273 ↗ |
| Action | Activate | “GSK159802 is a potent, inhaled, long acting selective beta-2-receptor agonist (LABA)” NCT00364273 ↗1“Beta-2 adrenergic receptor agonist” CHEMBL3545087 ↗ |
| Route | Inhaled | “GSK159802 is a potent, inhaled, long acting selective beta-2-receptor agonist (LABA)” NCT00364273 ↗ |
| Target | ADRB2 | “Beta-2 adrenergic receptor agonist” CHEMBL3545087 ↗ |